Announcement • Apr 17
ImExHS Limited, Annual General Meeting, May 20, 2026 ImExHS Limited, Annual General Meeting, May 20, 2026. Location: level 7, 32 martin place, sydney nsw 2000, Australia Reported Earnings • Mar 02
Full year 2025 earnings released: AU$0.056 loss per share (vs AU$0.058 loss in FY 2024) Full year 2025 results: AU$0.056 loss per share. Revenue: AU$29.0m (up 9.3% from FY 2024). Net loss: AU$2.88m (loss widened 9.8% from FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Healthcare Services industry in Australia. Announcement • Feb 20
ImExHS Limited to Report Fiscal Year 2025 Results on Feb 27, 2026 ImExHS Limited announced that they will report fiscal year 2025 results at 10:00 AM, AUS Eastern Standard Time on Feb 27, 2026 Board Change • Jan 05
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Damian Banks was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 01
First half 2025 earnings released: AU$0.062 loss per share (vs AU$0.034 loss in 1H 2024) First half 2025 results: AU$0.062 loss per share (further deteriorated from AU$0.034 loss in 1H 2024). Revenue: AU$13.7m (down 1.6% from 1H 2024). Net loss: AU$3.00m (loss widened 98% from 1H 2024). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. New Risk • Aug 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.1m free cash flow). Market cap is less than US$10m (AU$11.8m market cap, or US$7.72m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$409k net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AU$11.8m market cap, or US$7.69m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Jun 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$13.9m (US$9.06m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AU$13.9m market cap, or US$9.06m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • May 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (AU$18.2m market cap, or US$11.8m). Reported Earnings • Apr 05
Full year 2024 earnings released: AU$0.058 loss per share (vs AU$0.11 loss in FY 2023) Full year 2024 results: AU$0.058 loss per share (improved from AU$0.11 loss in FY 2023). Revenue: AU$26.5m (up 33% from FY 2023). Net loss: AU$2.63m (loss narrowed 41% from FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Mar 25
ImExHS Limited Announces Strategic Product Update IMEXHS Limited announced that the major software development for the New Value Proposition, to be branded Aquila+, is largely complete. The product is now installed and operating in eight sites and is being implemented for new contracts. The programme to develop Aquila+ commenced at the beginning of 2024. While development continues on further features, the platform began in Beta testing during fourth quarter of fiscal year 24 and is now a fully live commercial product. The timeline and cost to develop Aquila+ is in line with plan. The key objectives have been to: a) drive efficiencies and quality throughout the radiology workflow through an automated AI driven worklist allocation, system resilience, industry leading post sale service, fastest implementation time (less than one day as opposed to more than a week), and highest security standard. b) improve the productivity of radiologists - including an ability to sit across multiple PACS systems for teleradiology, access to hundreds of FDA and CE approved AI diagnostic tools, access to faster image downloads, reduced clicks and automated next study opening, and AI enabled report writing. c) drive operational benefits for IMEXHS through - sharply reduced engineering operations cost, and sharply reduced storage and compute costs via the multi-tenant architecture. The company is now selling and contracting Aquila+ which is the successor to Aquila v3.6. The two platforms will co-exist for about twelve months. While Aquila+ takes with it all the functionality of Aquila v3.6, it adds a much wider capability of the entire platform and embedded menu of tools, making Aquila+ a unique offering in the market. One of the key criteria for the New Value Proposition development is to provide the highest security standards for medical data in the sector. IMEXHS has received final audit recommendation for ISO 27001 Certification for the new platform development Aquila++ further to this certification, Compensar, a large compensation fund with 22 hospitals, has tested penetration and other security features of Aquila+ against global competitors. As a result, it has selected and installed Aquila+ in the first of its 22 hospitals. The ability to reduce storage and compute costs, increased visualisation speed, seamless updating, and the achievement of the highest service levels are made possible by using Kubernetes and multi-tenant architecture. Formal market launches and digital marketing in Latin America commence in April 2025. New Risk • Mar 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.6m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Market cap is less than US$10m (AU$15.6m market cap, or US$9.84m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • Mar 01
Full year 2024 earnings released: AU$0.058 loss per share (vs AU$0.10 loss in FY 2023) Full year 2024 results: AU$0.058 loss per share (improved from AU$0.10 loss in FY 2023). Revenue: AU$26.6m (up 34% from FY 2023). Net loss: AU$2.63m (loss narrowed 37% from FY 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • Feb 20
ImExHS Limited, Annual General Meeting, Apr 10, 2025 ImExHS Limited, Annual General Meeting, Apr 10, 2025. Location: at its offices at level 7, 32 martin place, sydney nsw 2000 Australia New Risk • Dec 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$2.1m free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (7.1% increase in shares outstanding). Market cap is less than US$100m (AU$17.1m market cap, or US$10.6m). New Risk • Nov 28
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.3m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.1m free cash flow). Market cap is less than US$10m (AU$15.3m market cap, or US$9.93m). Minor Risks Shareholders have been diluted in the past year (7.1% increase in shares outstanding). Significant insider selling over the past 3 months (AU$78k sold). New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$2.1m free cash flow). Minor Risks Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (AU$22.8m market cap, or US$15.4m). Announcement • Mar 22
ImExHS Limited, Annual General Meeting, Apr 23, 2024 ImExHS Limited, Annual General Meeting, Apr 23, 2024, at 11:00 E. Australia Standard Time. Location: 122 O'Riordan Street, Mascot Sydney Australia Agenda: To consider remuneration report; to consider re-election of director dr douglas Lingard; to consider re-election of director mr damian banks; to consider grant of options to the chief executive officer; to consider grant of options to non-executive director, MR DAMIAN BANKS; and to transact such other business matters. Announcement • Mar 11
ImExHS Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. ImExHS Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,727,273
Price\Range: AUD 0.55
Discount Per Security: AUD 0.033
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 01
Full year 2023 earnings released: AU$0.10 loss per share (vs AU$0.085 loss in FY 2022) Full year 2023 results: AU$0.10 loss per share (further deteriorated from AU$0.085 loss in FY 2022). Revenue: AU$19.9m (up 16% from FY 2022). Net loss: AU$4.19m (loss widened 38% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Price Target Changed • Feb 29
Price target decreased by 18% to AU$1.50 Down from AU$1.82, the current price target is provided by 1 analyst. New target price is 142% above last closing price of AU$0.62. Stock is up 51% over the past year. The company posted a net loss per share of AU$0.085 last year. Announcement • Feb 23
ImExHS Limited to Report Fiscal Year 2023 Results on Feb 29, 2024 ImExHS Limited announced that they will report fiscal year 2023 results on Feb 29, 2024 Reported Earnings • Sep 05
First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.053 loss in 1H 2022) First half 2023 results: AU$0.055 loss per share (further deteriorated from AU$0.053 loss in 1H 2022). Revenue: AU$8.86m (down 7.5% from 1H 2022). Net loss: AU$2.29m (loss widened 31% from 1H 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Sep 02
ImExHS Limited Provides Revenue Guidance for the Second Half and Full Year of 2023 ImExHS Limited provided revenue guidance for the second half and full year of 2023. For the second half of 2023, the company expected revenue growth of 16% - 33% versus first half of fiscal year 2023; and expected revenue growth of 33% - 53% versus second half of fiscal year 2022.For the fiscal year 2023 revenue is expected to be between $19.0 million to $20.5 million (vs $17.1 million in fiscal year 2022). New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 4.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (AU$24.9m market cap, or US$16.2m). New Risk • Jun 30
New major risk - Revenue and earnings growth Earnings have declined by 4.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 4.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$24.9m market cap, or US$16.5m). New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$20.7m market cap, or US$14.0m). Reported Earnings • Mar 03
Full year 2022 earnings released: AU$0.085 loss per share (vs AU$0.15 loss in FY 2021) Full year 2022 results: AU$0.085 loss per share (improved from AU$0.15 loss in FY 2021). Revenue: AU$17.3m (up 27% from FY 2021). Net loss: AU$3.04m (loss narrowed 35% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Price Target Changed • Jan 31
Price target decreased by 10% to AU$1.82 Down from AU$2.03, the current price target is provided by 1 analyst. New target price is 314% above last closing price of AU$0.44. Stock is down 62% over the past year. The company is forecast to post a net loss per share of AU$0.056 next year compared to a net loss per share of AU$0.15 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Damian Banks was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Sep 01
Price target decreased to AU$2.03 Down from AU$2.53, the current price target is provided by 1 analyst. New target price is 306% above last closing price of AU$0.50. Stock is down 66% over the past year. The company is forecast to post a net loss per share of AU$0.031 next year compared to a net loss per share of AU$0.15 last year. Announcement • Sep 01
ImExHS Limited has completed a Follow-on Equity Offering in the amount of AUD 1.975112 million. ImExHS Limited has completed a Follow-on Equity Offering in the amount of AUD 1.975112 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,114,816
Price\Range: AUD 0.48
Discount Per Security: AUD 0.0288
Transaction Features: Reserved Share Offering; Rights Offering Reported Earnings • Aug 31
First half 2022 earnings released: AU$0.053 loss per share (vs AU$0.092 loss in 1H 2021) First half 2022 results: AU$0.053 loss per share (up from AU$0.092 loss in 1H 2021). Revenue: AU$9.59m (up 84% from 1H 2021). Net loss: AU$1.74m (loss narrowed 37% from 1H 2021). Over the next year, revenue is forecast to grow 18%, compared to a 37% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Announcement • Aug 26
ImExHS Limited to Report First Half, 2022 Results on Aug 30, 2022 ImExHS Limited announced that they will report first half, 2022 results on Aug 30, 2022 Announcement • Aug 03
ImExHS Limited Revises Earnings Guidance for the Fiscal Year 2022 ImExHS Limited revised earnings guidance for the fiscal year 2022. The company expects Revenue between $18.0 million to $20.5 million (vs $13.4 million in fiscal year 2021). This is a reduction from previous guidance of $19.5 million to $22.0 million due principally to the Company's decision to cancel a material contract for poor payment performance. Major Estimate Revision • Apr 30
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from AU$17.3m to AU$20.4m. EPS estimate unchanged from AU$0.018 at last update. Healthcare Services industry in Australia expected to see average net income growth of 24% next year. Consensus price target of AU$2.54 unchanged from last update. Share price fell 2.4% to AU$0.82 over the past week. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Damian Banks was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 01
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: AU$0.15 loss per share (down from AU$0.15 loss in FY 2020). Revenue: AU$13.6m (up 24% from FY 2020). Net loss: AU$4.70m (loss widened 30% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 44%. Over the next year, revenue is forecast to grow 27%, compared to a 93% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Feb 28
ImExHS Limited, Annual General Meeting, May 19, 2022 ImExHS Limited, Annual General Meeting, May 19, 2022, at 10:00 AUS Eastern Standard Time. Announcement • Feb 21
ImExHS Limited to Report Fiscal Year 2021 Results on Feb 28, 2022 ImExHS Limited announced that they will report fiscal year 2021 results on Feb 28, 2022 Announcement • Jan 20
IMEXHS Launches Aquila in the Thai Market IMEXHS Limited announced it has received approval from the Thai Food and Drug Administration (FDA) for the Company's PACS technology (HIRUKO Essential software suite). The Company has also signed an international software distribution agreement with BJC Healthcare Company, which is part of the Berli Jucker Group (BJC), a company with a remarkable history that spans over 135 years. BJC Healthcare is a leading distributor of medical equipment and an innovative system for healthcare professionals and institutions. BJC's medical division has operated for over 40-years and is comprised of three main business units: Medical Innovation Technology, Surgery Solutions and Life-Care Saving Divisions. BJC Healthcare currently employs over 350 skilled employees. IMEXHS has received its first Aquila in the Cloud order from BJC for the Siriraj Hospital's Mobile Stroke Unit located in Bangkok. The contract with Siriraj Hospital is volume based and billed in USD. The Siriraj Hospital is Thailand's oldest and hospital and one of the in Southeast Asia, with a capacity of over 2,000 beds. The hospitalreceives over 3 million patient visits per year. The Stroke Unit involves a special ambulance that connects the first responders in the ambulance to the hospital's experts. IMEXHS will provide Siriraj's Stroke Unit with the Company's robust PACS system and Universal Viewer to provide quick access to brain images.The Siriraj Stroke Unit considered several options from different vendors before choosing IMEXHS's product due to its flexibility and modern technology. Major Estimate Revision • Dec 22
Consensus revenue estimates fall by 11% The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from AU$14.9m to AU$13.2m. Forecast losses increased from -AU$0.09 to -AU$0.11 per share. Healthcare Services industry in Australia expected to see average net income growth of 40% next year. Consensus price target broadly unchanged at AU$2.55. Share price was steady at AU$0.98 over the past week. Announcement • Dec 20
ImExHS Limited Provides Consolidated Revenue Guidance for the Fiscal Year 2021 ImExHS Limited provided consolidated revenue guidance for the fiscal year 2021. The consolidated fiscal year 2021 revenue is expected to be $13.2 million to $13.9 million. Recent Insider Transactions • Nov 09
Non-Executive Chairman recently bought AU$64k worth of stock On the 3rd of November, Douglas Flynn bought around 51k shares on-market at roughly AU$1.27 per share. This was the largest purchase by an insider in the last 3 months. Douglas has been a buyer over the last 12 months, purchasing a net total of AU$146k worth in shares. Recent Insider Transactions • Oct 07
Independent Non-Executive Director recently bought AU$59k worth of stock On the 1st of October, Douglas Lingard bought around 43k shares on-market at roughly AU$1.39 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$434k more in shares than they have sold in the last 12 months. Price Target Changed • Aug 30
Price target decreased to AU$2.48 Down from AU$3.13, the current price target is provided by 1 analyst. New target price is 66% above last closing price of AU$1.49. Stock is down 27% over the past year. Recent Insider Transactions • May 13
Independent Non-Executive Director recently bought AU$99k worth of stock On the 10th of May, Douglas Lingard bought around 49k shares on-market at roughly AU$2.02 per share. In the last 3 months, there was an even bigger purchase from another insider worth AU$173k. Insiders have collectively bought AU$661k more in shares than they have sold in the last 12 months. Reported Earnings • Apr 02
Full year 2020 earnings released: AU$0.15 loss per share (vs AU$0.31 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: AU$11.0m (up 42% from FY 2019). Net loss: AU$3.62m (loss narrowed 40% from FY 2019). Recent Insider Transactions • Mar 07
Independent Non-Executive Director recently bought AU$173k worth of stock On the 3rd of March, Damian Banks bought around 78k shares on-market at roughly AU$2.20 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$860k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 27
Full year 2020 earnings released: AU$0.15 loss per share (vs AU$0.32 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: AU$11.0m (up 42% from FY 2019). Net loss: AU$3.62m (loss narrowed 40% from FY 2019). Announcement • Feb 17
ImExHS Limited to Report Fiscal Year 2020 Results on Feb 26, 2021 ImExHS Limited announced that they will report fiscal year 2020 results on Feb 26, 2021 Is New 90 Day High Low • Feb 05
New 90-day high: AU$2.00 The company is up 33% from its price of AU$1.50 on 06 November 2020. The Australian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 26% over the same period. Announcement • Dec 15
Imexhs Limited Announces Executive Changes IMEXHS Limited announced that Mr. Peter Webse has resigned as Joint Company Secretary with effect from close of business 12 December 2020. The Board wishes to thank Peter for his contribution as Company Secretary since joining the Company in May 2018. Ms Reena Minhas who was appointed on 1 October 2020 will continue as sole Company Secretary. Announcement • Aug 18
ImExHS Limited announced that it expects to receive AUD 0.5 million in funding from Domatorisaro Pty Ltd ImExHS Limited (ASX:IME) announced a private placement of 16,666,667 shares at a price of AUD 0.03 per share for gross proceeds of AUD 500,000.01 on August 17, 2020. The transaction will include participation from Domatorisaro Pty Ltd, an entity controlled by Doug Lingard, a director of the company. The transaction is subject to the approval of the shareholders of the company at a general meeting to be held late October/November 2020. The company expects to close the transaction on November 16, 2020. Announcement • Aug 17
ImExHS Limited to Report First Half, 2020 Results on Aug 31, 2020 ImExHS Limited announced that they will report first half, 2020 results on Aug 31, 2020 
